The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.
Voting with their wallets, pharmas say no thanks to change
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
In PhRMA-White House emails, little sizzle, less scandal
Congressional Republicans are trumpeting a cache of emails that give a glimpse into how the White House’s deal with the pharma industry on healthcare reform came together. There’s not much ‘there’ there, but there are some titillating glimpses into the legislative sausage factory.
Co-pay cards and coupons sway 2 million US seniors, study says
The National Coalition on Health Care took aim at co-pay cards and coupons with a report suggesting that they might push 2 million US seniors to opt for more expensive branded drugs over generics.
President’s budget would deal a wallop to biopharma wallets
President Obama’s proposed 2013 budget would mandate an estimated $156 billion in new rebates to low-income seniors through Medicare over the next decade – discounts that would come out of the pockets of drug companies and could cost tens of thousands of jobs, according to PhRMA.
Aging Committee raps pharma on brand drug price hikes
Armed with AARP and Kaiser Family research, members of the Senate Special Committee on Aging asked panelists why brand drug prices in the US continue to increase, while other countries pay half as much for the same products.
PhRMA has committed to finding $80 billion in savings on drugs sold in the US over 10 years, including selling drugs at half-price to seniors in the Medicare Part D “donut hole” coverage gap.